公开(公告)号：US20240360182A1

公开(公告)日：2024-10-31

申请号：US18768701

申请日：2024-07-10

Applicant: The Trustees of the University of Pennsylvania ,  Inovio Pharmaceuticals, Inc.

Inventor： David B. Weiner ,  Bernadette Ferraro ,  Jian Yan ,  Patricia A. Brown ,  Rodney A. Bowling ,  Douglas R. Kern ,  Mathura P. Ramanathan ,  Niranjan Y. Sardesai ,  Karuppiah Muthumani

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/135 ,  A61K39/39 ,  A61M37/00 ,  A61N1/32 ,  C12N7/00 ,  G01N33/569

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/135 ,  A61K39/39 ,  A61M37/00 ,  A61N1/327 ,  C12N7/00 ,  G01N33/56983 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/552 ,  C12N2770/32122 ,  C12N2770/32134 ,  G01N2333/09 ,  G01N2469/20

Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.

公开(公告)号：US20240351977A1

公开(公告)日：2024-10-24

申请号：US18579943

申请日：2022-08-12

Applicant: Lapix Therapeutics, Inc.

Inventor： Anas M. Fathallah ,  Scott D. Larsen ,  Abdulraouf Ramadan

IPC: C07C237/12 ,  A61K9/127 ,  A61K39/00 ,  A61K39/39 ,  C07C271/22 ,  C12N15/86

CPC classification number: C07C237/12 ,  A61K9/127 ,  A61K39/39 ,  C07C271/22 ,  C12N15/86 ,  A61K2039/542 ,  A61K2039/55555 ,  C12N2750/14143

Abstract: Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula: wherein values for the variables (e.g., X, R) are as described herein.

公开(公告)号：US20240335521A1

公开(公告)日：2024-10-10

申请号：US18591479

申请日：2024-02-29

Applicant: Vaxcyte, Inc.

Inventor： Christopher Iain GRAINGER ,  Sandrine BARBANEL ,  Shashwati Ujwalkumar ATWE

IPC: A61K39/09 ,  A61K39/00 ,  A61K39/095 ,  A61K39/102 ,  A61K39/39 ,  A61K47/02

CPC classification number: A61K39/092 ,  A61K39/095 ,  A61K39/102 ,  A61K39/39 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/6031 ,  A61K2039/6087

Abstract: The present disclosure provides stabilized vaccine compositions that resist the formation of unsuitable adjuvant flocculant or aggregates. The present disclosure further provides methods of using such compositions to induce immune responses against infections in subjects.

公开(公告)号：US20240335473A1

公开(公告)日：2024-10-10

申请号：US18745733

申请日：2024-06-17

Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education

Inventor： Greg M. Delgoffe

IPC: A61K35/17 ,  A61K31/341 ,  A61K31/429 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/17 ,  A61K38/20 ,  A61K39/00 ,  A61K39/39 ,  A61K45/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K31/341 ,  A61K31/429 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/1774 ,  A61K38/2013 ,  A61K39/00119 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C12N5/0636 ,  A61K2039/5158 ,  A61K2039/876 ,  A61K45/05 ,  A61K2800/78 ,  C12N2501/39 ,  C12N2501/999

Abstract: The present disclosure provides methods for expanding tumor-infiltrating lymphocytes (TILs), such as tumor-infiltrating T cells, utilizing an agonist of PGC1α in vivo, ex vivo, or both. Exhausted T cells present in the TIL population fail to effectively proliferate, produce cytokines, or kill target cells. The present disclosure provides methods to correct these defects through the use of pharmacologic agents to reprogram the metabolism of the exhausted intratumoral T cells. Exemplary agonists of PGC1α include proliferator-activated receptor (PPAR)-gamma agonists (e.g., a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar), AMPK activators (e.g., 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR), and sirtuin activators (e.g., resveratrol, SRT1720, SRT2104, SRT2183, SRT1460). Also provided are kits can compositions that can be used with such methods.

公开(公告)号：US12109190B2

公开(公告)日：2024-10-08

申请号：US17822027

申请日：2022-08-24

Applicant: Amazentis SA

Inventor： Anurag Singh ,  Davide D'Amico ,  Penelope Andreux ,  William Blanco-Bose ,  Christopher L. Rinsch

IPC: A61K31/37 ,  A61K31/335 ,  A61K39/00 ,  A61K39/145 ,  A61K39/39 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/08 ,  A61P21/00 ,  A61P31/16 ,  A61P35/00 ,  C07D311/80

CPC classification number: A61K31/37 ,  A61K31/335 ,  A61K39/0011 ,  A61K39/145 ,  A61K39/39 ,  A61P31/16 ,  A61K2039/55 ,  A61K2039/55511 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/08 ,  A61P21/00 ,  A61P35/00 ,  C07D311/80 ,  A61K2300/00 ,  A61K31/366

Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.

公开(公告)号：US20240327443A1

公开(公告)日：2024-10-03

申请号：US18733207

申请日：2024-06-04

Applicant: ADJUVANCE TECHNOLOGIES, INC. ,  MEMORIAL SLOAN KETTERING CANCER CENTER

Inventor： David Y. GIN ,  Eric CHEA ,  Alberto FERNANDEZ-TEJADA ,  Jeffrey GARDNER ,  Jason LEWIS ,  Philip LIVINGSTON ,  J. Tyler MARTIN ,  Lars NORDSTROEM ,  Naga Vara Kishore PILLARSETTY ,  Govind RAGUPATHI ,  Derek TAN

IPC: C07H1/00 ,  A61K31/7024 ,  A61K39/00 ,  A61K39/02 ,  A61K39/08 ,  A61K39/10 ,  A61K39/39 ,  A61P31/04 ,  C07H13/04 ,  C07H13/06 ,  C07H13/08 ,  C07J63/00

CPC classification number: C07H1/00 ,  A61K31/7024 ,  A61K39/08 ,  A61K39/099 ,  A61K39/39 ,  A61P31/04 ,  C07H13/04 ,  C07H13/06 ,  C07H13/08 ,  C07J63/008 ,  A61K2039/10 ,  A61K2039/55583

Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

公开(公告)号：US12102673B2

公开(公告)日：2024-10-01

申请号：US18334497

申请日：2023-06-14

Applicant: Valneva Austria GmbH

Inventor： Jana Barbero Calzado ,  Mario Nebenführ ,  Robert Schlegl ,  Michael Weber ,  Jürgen Heindl-Wruss

IPC: A61K39/12 ,  A61K9/00 ,  A61K39/00 ,  A61K39/39 ,  A61P31/14 ,  C07K14/18 ,  C12N7/00 ,  C12N7/02 ,  C12N7/06

CPC classification number: A61K39/12 ,  A61K39/39 ,  A61P31/14 ,  C07K14/18 ,  C07K14/1825 ,  C12N7/00 ,  C12N7/02 ,  C12N7/06 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/5258 ,  A61K2039/55505 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2770/24163 ,  Y02A50/30

Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

公开(公告)号：US20240309037A1

公开(公告)日：2024-09-19

申请号：US18437424

申请日：2024-02-09

Applicant: THE UNIVERSITY OF MONTANA

Inventor： David Burkhart ,  George Ettenger ,  Jay Evans ,  Kendal T. Ryter ,  Alyson Smith

IPC: C07H13/08 ,  A61K39/04 ,  A61K39/39 ,  A61P37/04 ,  C07H15/04

CPC classification number: C07H13/08 ,  A61K39/04 ,  A61K39/39 ,  A61P37/04 ,  C07H15/04

Abstract: Disclosed herein are diaryl trehalose compounds and methods of use thereof, for example as vaccine adjuvants.

公开(公告)号：US12091393B2

公开(公告)日：2024-09-17

申请号：US17287914

申请日：2019-10-22

Applicant: The Regents of the University of California

Inventor： Dennis Carson ,  Mary Patricia Corr ,  Howard B. Cottam ,  Tomoko Hayashi ,  Nikunj Shukla

IPC: C07D277/44 ,  A61K39/39 ,  A61K39/00

CPC classification number: C07D277/44 ,  A61K39/39 ,  A61K2039/55511

Abstract: Compounds of formulae (I)-(VD):

A1-Q-L1-A2-L2-Z  Formula I

are useful for enhancing or prolonging an immune response, such as, in a vaccine as an adjuvant or a co-adjuvant.

公开(公告)号：US20240299523A1

公开(公告)日：2024-09-12

申请号：US18660419

申请日：2024-05-10

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Leena Shriram Bagle ,  Amardeep Singh Bhupender Bhalla ,  Miguel Angel Garcia ,  Lei Hu ,  Lakshmi Khandke ,  Avvari Krishna Prasad ,  Cindy Xudong Yang

IPC: A61K39/09 ,  A61K39/00 ,  A61K39/39

CPC classification number: A61K39/092 ,  A61K39/39 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/70

Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.